Associations
Brighton & Hove City Council and the UK Government are marking Dementia Action Week (19-25 May 2025) by supporting the Alzheimer's Society's national campaign to promote early diagnosis and raise awareness of dementia symptoms. The campaign encourages people to take action by recognising the signs of
Associations
A significant breakthrough in the diagnosis of Alzheimer's disease has been achieved with the approval of the first blood test by the U.S. Food and Drug Administration (FDA). The test, known as the Lumipulse G pTau217/ss-Amyloid 1-42 Plasma Ratio, detects amyloid plaques, a hallmark of Alzheimer&
Associations
In Wales, a worrying trend is emerging: half of adults are unaware that vision changes can be a symptom of dementia, according to a report by Alzheimer's Society Cymru. This lack of awareness is pressing, as dementia can cause significant issues with vision, including judging distances, perceiving object
Diseases
The US Food and Drug Administration (FDA) has cleared the Lumipulse G pTau217/È-Amyloid 1-42 Plasma Ratio (by Fujirebio Diagnostics, Inc.) for marketing, a game-changing in vitro diagnostic device that uses blood tests to aid in diagnosing Alzheimer's disease. This innovative test measures two proteins found in human
Diseases
A new study published in Biomolecules, a peer-reviewed journal, suggests that serotonin 5HT [ [1A] ] receptors may be affected in Parkinson's disease, providing a potential target for diagnostic and therapeutic approaches. Using the selective 5HT [ [1A] ] receptor positron emission tomography (PET) imaging agent, [[superscript]18F]mefway, researchers at the
Diseases
The U.S. Food and Drug Administration (FDA) has granted marketing clearance to the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, a blood test designed to detect Alzheimer disease in patients aged 55 and older who are showing signs of the disease. This breakthrough diagnostic tool measures the levels of
Diseases
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Leqembi, a medicinal product for the treatment of early Alzheimer's disease in a restricted population of patients. This decision was based on a re-examination procedure, following which
Diseases
A recent preprint study published on medrxiv.org investigated the potential of integrating schizophrenia-associated genetic risk variants to enhance Alzheimer's disease (AD) prediction. The study utilized large-scale genome-wide association study (GWAS) data from 1,126,563 individuals with AD and 320,404 individuals with schizophrenia. By incorporating top
Alzheimer's disease
A landmark Alzheimer's research paper was retracted in June 2024 due to fraud allegations, leaving the scientific community questioning the validity of the research and its potential impact. However, despite the setback, research into amyloid beta, the subject of the retracted paper, continues to yield promising results. Two
Alzheimer's disease
The World Economic Forum's initiative, Davos Alzheimer's Collaborative, has invested $700 million over six years into drug development and healthcare diagnostics to combat Alzheimer's disease, which is one of the biggest causes of death and disability worldwide. Research has shown that a healthy lifestyle
Alzheimer's disease
Cambridge scientists have warned that Alzheimer's treatments, which claim to slow down the progression of the disease, may not be able to reduce the number of deaths from dementia. The treatments, lecanemab and donanemab, have been hailed as breakthroughs in the fight against Alzheimer's, but critics
Alzheimer's disease
Alzheimer's disease, a progressive disorder, causes brain cells to waste away and die, leading to a decline in memory, thinking, and social abilities. In the United States, an estimated 5.8 million people lived with Alzheimer's in 2020, a number projected to nearly triple to 14
